Real-world Study of Treatment Outcomes in Chronic Inflammatory Demyelinating Polyneuropathy/Polyradiculoneuropathy (CIDP)

This study is an observational, ambispective, descriptive, non-interventional study of people with a chronic inflammatory demyelinating polyneuropathy/polyradiculoneuropathy (CIDP) diagnosis in the United States with residual impairment, disability, or neurological deficits after at least three months of treatment with standard of care therapy. The study is expected to last two years. Enrollment is expected to continue for one year. Depending on when the participant is enrolled, a participant can be followed for between one and two years, through the end of study, approximately two years after the study starts.

NCT Number	NCT06968975
Lead Sponsor	Sanofi
Conditions	Polyneuropathy, Inflammatory Demyelinating, Chronic
Enrollment	200 participants
Start Date	2025-04-11
Primary Completion	2027-05-17 (estimated)
Study Completion	2027-05-17 (estimated)
Updated on ClinicalTrials.gov	2026-07-24